Proliferating cell nuclear antigen(PCNA)overexpression in hepatocellular carcinoma predicts poor prognosis as determined by bioinformatic analysis  

作　　者：Dan-Dan Li Jia-Wei Zhang Rui Zhang Jie-Hong Xie Kuo Zhang Gui-Gao Lin Yan-Xi Han Rong-Xue Peng Dong-Sheng Han Jie Wang Jing Yang Jin-Ming Li 

机构地区：[1]National Center for Clinical Laboratories,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing 100005,China [2]Graduate School,Peking Union Medical College,Chinese Academy of Medical Sciences,Beijing 100730,China [3]Beijing Engineering Research Center of Laboratory Medicine,Beijing Hospital,Beijing 100005,China.

出　　处：《Chinese Medical Journal》2021年第7期848-850,共3页中华医学杂志（英文版）

基　　金：National Natural Science Foundation of China(No.81772273)。

摘　　要：To the Editor:Nowadays,many methods have been taken in early diagnosis and clinical therapy,but the overall survival(OS)of hepatocellular carcinoma(HCC)patients remains unsatisfactory.[1]Therefore,it is seriously significant to identify novel prognostic biomarkers and better to find the promising therapeutic targets.

关 键 词：HEPATOCELLULAR DIAGNOSIS CLINICAL 

分 类 号：R735.7[医药卫生—肿瘤] Q811.4[医药卫生—临床医学]